Biomarker Panels for Discriminating Risk of CKD Progression in Children
Journal of the American Society of Nephrology · 2025-06 · 36 (6) · 1105-1115
DOI: 10.1681/asn.0000000602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 16.01.2025. Verfasst von Jason H Greenberg und 18 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, Division of Diabetes, Endocrinology, and Metabolic Diseases.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Key Points Plasma biomarkers (kidney injury molecule-1, KIM-1), urine biomarkers (EGF/creatinine and urine albumin-creatinine ratio), and eGFR identified four prognostic groups in children with CKD progression. A panel of biomarkers may better capture the complexity of kidney disease in children and may allow for a broader assessment of kidney health.
Background
We have previously studied biomarkers of tubular health (EGF), injury (kidney injury molecule-1 [KIM-1]), dysfunction ( α -1 microglobulin), and inflammation (TNF receptor-1, TNF receptor-2, monocyte chemoattractant protein-1, YKL-40, and soluble urokinase plasminogen activator receptor) and demonstrated that plasma KIM-1, TNF receptor-1, TNF receptor-2, urine KIM-1, EGF, monocyte chemoattractant protein-1, and urine α -1 microglobulin are each independently associated with CKD progression in children. In this study, we used bootstrapped survival trees to identify a combination of biomarkers to predict CKD progression in children.
Methods
The Chronic Kidney Disease in Children (CKiD) Cohort Study prospectively enrolled children aged 6 months to 16 years with an eGFR of 30–90 ml/min per 1.73 m 2 . We measured biomarkers in stored plasma and urine collected 5 months after study enrollment. The primary outcome of CKD progression was a composite of 50% eGFR decline or kidney failure. We constructed a regression tree–based model for predicting the time to the composite event, using a panel of clinically relevant biomarkers with empirically derived thresholds, in addition to conventional risk factors.
Results
Of the 599 children included, the median age was 12 years (interquartile range [IQR], 8–15), 371 (62%) were male, baseline urine protein-creatinine ratio was 0.33 (IQR, 0.12–0.95) mg/mg, and baseline eGFR was 53 (IQR, 40–66) ml/min per 1.73 m 2 . Overall, 205 children (34%) reached the primary outcome of CKD progression. A single regression tree–based model using the most informative predictors with data-driven biomarker thresholds suggested a final set of four prognosis groups. In the final model, urine albumin/creatinine was the variable with the highest importance and along with urine EGF/creatinine identified the highest risk group of 24 children, 100% of whom developed CKD progression at a median time of 1.3 years (95% confidence interval [CI], 1.0 to 1.7). When the regression tree–derived risk group classifications were added to prediction models including the clinical risk factors, the C-statistic increased from 0.76 (95% CI, 0.71 to 0.80) to 0.85 (95% CI, 0.81 to 0.88).
Conclusions
Using regression tree–based methods, we identified a biomarker panel of urine albumin/creatinine, urine EGF/creatinine, plasma KIM-1, and eGFR, which significantly improved discrimination for CKD progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Nephrology, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut.
- Clinical and Translational Research Accelerator, Yale University School of Medicine, New Haven, Connecticut.
- Department of Epidemiology, University of Colorado, Denver, Colorado.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, New York.
- Division of Nephrology, Department of Physiology and Biophysics and Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
- Section of Nephrology, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
ORCID-Profile: Jason H Greenberg, Alison G Abraham, Yunwen Xu, Jeffrey R Schelling, Steven G Coca, Sarah J Schrauben, F Perry Wilson, Ramachandran S Vasan, Orlando M Gutiérrez, Joachim H Ix, Chirag R Parikh
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Greenberg, J. H., Abraham, A. G., Xu, Y., Schelling, J. R., Coca, S. G., Schrauben, S. J., Wilson, F. P., Waikar, S. S., Vasan, R. S., Gutiérrez, O. M., Shlipak, M. G., Ix, J. H., Warady, B. A., Kimmel, P. L., Bonventre, J. V., Parikh, C. R., Denburg, M., Furth, S., & CKD Biomarkers Consortium (2025). Biomarker Panels for Discriminating Risk of CKD Progression in Children. Journal of the American Society of Nephrology, 36(6), 1105-1115. https://doi.org/10.1681/asn.0000000602
Vancouver
Greenberg JH, Abraham AG, Xu Y, Schelling JR, Coca SG, Schrauben SJ, et al. Biomarker Panels for Discriminating Risk of CKD Progression in Children. Journal of the American Society of Nephrology. 2025;36(6):1105-1115. doi:10.1681/asn.0000000602
BibTeX
@article{Greenberg2025,
author = {Greenberg, Jason H and Abraham, Alison G and Xu, Yunwen and Schelling, Jeffrey R and Coca, Steven G and Schrauben, Sarah J and Wilson, F Perry and Waikar, Sushrut S and Vasan, Ramachandran S and Gutiérrez, Orlando M and Shlipak, Michael G and Ix, Joachim H and Warady, Bradley A and Kimmel, Paul L and Bonventre, Joseph V and Parikh, Chirag R and Denburg, Michelle and Furth, Susan and CKD Biomarkers Consortium, CKD Biomarkers Consortium},
title = {Biomarker Panels for Discriminating Risk of CKD Progression in Children},
journal = {Journal of the American Society of Nephrology},
year = {2025},
volume = {36},
number = {6},
pages = {1105--1115},
doi = {10.1681/asn.0000000602}
}
EUVIMED